US Stocks Movement: Nanobiotix surged on October 27 due to clinical data on melanoma and NBTXR3
Bitget异动解读2026/10/27 19:45Interpretation of Nanobiotix's Surge on October 27
Keywords: Melanoma clinical data, NBTXR3
On October 24, 2026, Nanobiotix announced the final data from a phase I study of JNJ-1900 NBTXR3 combined with immune checkpoint inhibitors for the treatment of anti-PD-1 resistant primary cutaneous melanoma: objective response rate in 24 patients was 41.7% (10 out of 24), including 4 complete remissions; disease control rate was 75% (18 out of 24), and median overall survival was 17.8 months.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Strive buys 15,124 Bitcoin in October, closes in on top treasury holders
Meta Platforms launches Spaces feature in its Muse app
Microsoft gradually terminates the rental of Oracle AI cloud computing transactions
Crypto prices
More
